Search

Displaying results 1671 - 1680 of 4335 in total
  1. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.

  2. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia

  3. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    As isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636]. … The prodrug formulation of isavuconazole is FDA- and EMA-approved and is marketed under the trade name Cresemba for the treatment of invasive aspergillosis and mucormycosis as oral or intravenous administration

  4. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotin...

  5. Drug

    Pentastarch

    go.drugbank.com/drugs/DB09111
    ApprovedWithdrawn

    Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. It is sold under the name Pentaspan by Bris...

  6. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.

  7. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  8. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  9. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  10. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.